Answers are grounded in this paper and cite their sources.
Pembrolizumab is a novel immune checkpoint inhibitor approved for use in non-small cell lung carcinoma. There have been a few cases that have associated adverse renal outcomes with pembrolizumab. We present a case of acute kidney injury in a patient on pembrolizumab who was noted to have acute tubulointerstitial nephritis on renal biopsy. Pembrolizumab was discontinued and the patient was started on long-term corticosteroids with a taper. Her renal function improved partially with treatment.
No takes yet. Share an insight, caveat, or question.
Basnet et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: